Eltrombopag

• Description:

  Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].

• Product Name Alternative:

  SB-497115

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Bacterial; Thrombopoietin Receptor

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Apoptosis; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Eltrombopag.html

• Purity:

  99.94

• Solubility:

  DMSO : 8.33 mg/mL (ultrasonic)

• Smiles:

  O=C (C1=CC (C2=CC=CC (N/N=C3C (C) =NN (C4=CC=C (C) C (C) =C4) C/3=O) =C2O) =CC=C1) O

• Molecular Formula:

  C25H22N4O4

• Molecular Weight:

  442.47

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27 (2) :424-30.|[2]Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33 (1) :85-93.|[3]Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel) . 2021 Nov 9;10 (11) :1372.|[4]Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.|[5]Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47 (5) :1696-702.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Nano. 2024 Sep 10;18 (36) :24872-24897.|Acta Neuropathol Commun. 2025 Nov 4;13 (1) :223.|Alzheimers Res Ther. 2024 Jun 3;16 (1) :121.|Biomed Pharmacother. 2025 Jun 20:189:118246.|bioRxiv. 2025 March 03.|bioRxiv. 2025 Sep 13.|Blood Adv. 2017 Feb 28;1 (7) :468-476.|BMC Cancer. 2020 Nov 30;20 (1) :1171.|Cell Death Discov. 2024 Oct 26;10 (1) :453.|Cells. 2022 Jan 18;11 (3) :319.|Curr Microbiol. 2021 Apr;78 (4) :1159-1167.|Eur J Pharmacol. 2024 Oct 29:177086.|J Pharm Biomed Anal. 2023 Oct 25:235:115683.|J Thromb Haemost. 2022 Aug;20 (8) :1900-1909.|J Transl Med. 2025 Jan 22;23 (1) :103.|Virology. 2023 Aug:585:205-214.|Viruses. 2019 Apr 25;11 (4) :385.|Eur J Clin Pharmacol. 2022 Oct;78 (10) :1657-1666.|Front Pharmacol. 2020 Nov 16:11:582625.

• CAS Number:

  496775-61-2